Compare RAYA & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | NXTS |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Agricultural Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2021 | 2021 |
| Metric | RAYA | NXTS |
|---|---|---|
| Price | $1.39 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.5K | ★ 157.0K |
| Earning Date | 04-28-2027 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.60 |
| 52 Week High | $6.14 | $53.90 |
| Indicator | RAYA | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 20.28 |
| Support Level | $0.75 | N/A |
| Resistance Level | $2.42 | $2.08 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 23.94 | 3.99 |
Erayak Power Solution Group Inc is engaged in the manufacturing, research and development (R&D), and wholesale and retail of power solution products. The group focuses on manufacturing new energy storage and inverter devices. Its product portfolio includes sine wave and off-grid inverters, inverters and gasoline generators, battery and smart chargers, and custom-designed products. The products are used principally in agricultural and industrial vehicles, recreational vehicles (RVs), electrical appliances, and outdoor living products. The company generates the majority of its revenue from Inverters. The company generates revenue from five main markets, which are China, Poland, Mexico, the U.K., and Portugal. It derives maximum revenue from China.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.